• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by iTeos Therapeutics Inc.

    5/8/25 7:43:41 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ITOS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    iTeos Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    46565G104

    (CUSIP Number)


    05/01/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    46565G104


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,656,640.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,656,640.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,656,640.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on 38,273,795 shares of Common Stock outstanding on April 22, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    46565G104


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,656,640.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,656,640.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,656,640.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 38,273,795 shares of Common Stock outstanding on April 22, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    CUSIP No.
    46565G104


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,490,694.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,490,694.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,490,694.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 38,273,795 shares of Common Stock outstanding on April 22, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended March 31, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    iTeos Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    321 Arsenal St, Watertown, MA 02472
    Item 2. 
    (a)Name of person filing:

    The reporting persons are: EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13D on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13D. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3, San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    46565G104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 2,656,640 Oleg Nodelman: 2,656,640 Qualified Fund: 2,490,694
    (b)Percent of class:

    EcoR1: 6.9% Oleg Nodelman: 6.9% Qualified Fund: 6.5%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 2,656,640 Oleg Nodelman: 2,656,640 Qualified Fund: 2,490,694

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 2,656,640 Oleg Nodelman: 2,656,640 Qualified Fund: 2,490,694

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:05/08/2025
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:05/08/2025
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:05/08/2025
    Get the next $ITOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITOS

    DatePrice TargetRatingAnalyst
    8/13/2024$31.00Overweight
    Wells Fargo
    12/13/2021$37.00 → $54.00Buy
    HC Wainwright & Co.
    11/12/2021$55.00 → $54.00Outperform
    SVB Leerink
    8/13/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings

    $ITOS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by iTeos Therapeutics Inc.

      SCHEDULE 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

      5/8/25 7:43:41 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by iTeos Therapeutics Inc.

      10-Q - iTeos Therapeutics, Inc. (0001808865) (Filer)

      4/28/25 4:36:51 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by iTeos Therapeutics Inc.

      DEFA14A - iTeos Therapeutics, Inc. (0001808865) (Filer)

      4/24/25 7:12:34 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Gall Matthew was granted 24,000 shares, increasing direct ownership by 37% to 89,429 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      3/11/25 8:00:05 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Mcgrath Yvonne was granted 15,300 shares, increasing direct ownership by 49% to 46,300 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      3/11/25 8:00:04 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Detheux Michel was granted 77,000 shares, increasing direct ownership by 131% to 135,903 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      3/11/25 8:00:10 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by iTeos Therapeutics Inc.

      SC 13G - iTeos Therapeutics, Inc. (0001808865) (Subject)

      11/21/24 8:27:38 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

      SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

      11/19/24 9:57:32 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by iTeos Therapeutics Inc.

      SC 13D/A - iTeos Therapeutics, Inc. (0001808865) (Subject)

      11/18/24 9:57:13 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

      - Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "The seco

      4/28/25 4:30:00 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

      WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois. Poster Presentation Details Abstract 3136, "EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment

      3/25/25 4:35:00 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      - Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial- EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25- Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a

      3/5/25 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Leadership Updates

    Live Leadership Updates

    See more
    • iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

      WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies. "As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer," said Michel Detheux, Ph.D., presi

      8/5/24 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

      WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its Board of Directors, effective March 7, 2024, where she will serve on the Company's audit committee. "Expanding our board with industry leaders and oncology veterans with commercial, scientific, and corporate portfolio strategy experience is of the utmost importance for iTeos. After the recent appointment of Servier's David Lee, we are thrilled to welcome Jill DeSimone to o

      3/6/24 7:01:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

      - Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Completed enrollment of third dose cohort in Phase 1 trial of EOS-984- Preclinical presentations on role of ENT1 at SITC Spring Scientific and profile of EOS-984 at AACR annual meeting- Cash and investment balance of $632.7 million as of December 31, 2023 expected to provide runway through 2026 across a number of impactful portfolio milestones- Oncology veterans Jill DeSimone and David K. Lee to join Board of Directors WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NA

      3/6/24 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Financials

    Live finance-specific insights

    See more
    • iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

      - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET WATERTOWN, Mass. and GOSSELIES, Belgium, Sept. 14, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stag

      9/14/24 2:30:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

      - First patients dosed in clinical trial of anti-TIGIT monoclonal antibody, EOS-448, in combination with pembrolizumab and with inupadenant in patients with solid tumors - Advanced clinical development of inupadenant, EOS-850, an A2A receptor antagonist, with initiation of an expansion in PD-1 resistant melanoma in combination with pembrolizumab as well as a planned study further exploring novel predictive biomarkers - Received full upfront payment of $625MM at closing of development and commercialization collaboration agreement with GSK for EOS-448 - Cash balance of $899.8MM as of September 30, 2021, providing runway into 2026 to support clinical development plans for EOS-448 and inupad

      11/10/21 4:01:00 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021

      CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 833-927-1758 (domestic) or 929-526-1599 (international) and refer to conference access code 861337. A live audio webcast of the event will also be accessible from

      11/3/21 7:00:00 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Gall Matthew bought $38,635 worth of shares (5,000 units at $7.73), increasing direct ownership by 8% to 65,429 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      11/19/24 7:59:14 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gall Matthew bought $41,850 worth of shares (5,000 units at $8.37), increasing direct ownership by 35% to 19,429 units (SEC Form 4)

      4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

      10/12/23 5:09:33 PM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ITOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on iTeos Therapeutics with a new price target

      Wells Fargo initiated coverage of iTeos Therapeutics with a rating of Overweight and set a new price target of $31.00

      8/13/24 7:50:52 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on ITeos Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of ITeos Therapeutics with a rating of Buy and set a new price target of $54.00 from $37.00 previously

      12/13/21 6:08:35 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on ITeos Therapeutics with a new price target

      SVB Leerink reiterated coverage of ITeos Therapeutics with a rating of Outperform and set a new price target of $54.00 from $55.00 previously

      11/12/21 7:04:30 AM ET
      $ITOS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care